Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETV vs TDF in HBV-related HCC after resection
NCT04032860Phase 4Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2017
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatitis B (HBV) and hepatocellular carcinoma (HCC) comparing ETV group with TDF group (2 arms). Primary endpoints: Overall Survival at 5 years and Recurrence-Free Survival at 5 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
tenofovir disoproxil fumarateentecavir
03
Conditions
hepatitis B (HBV)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04032860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032860.